Pegylated liposomal doxorubicin in ovarian cancer

Robert Strother*, Daniela Matei

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

The encapsulation of doxorubicin in a pegylated liposomal matrix led to a reformulated agent with a different toxicity profile and improved clinical utility. Liposomal doxorubicin is devoid of the cardiac toxicity associated with doxorubicin, but is associated with predictable muco-cutaneous toxicity. The liposomal formulation leads to improved delivery to the target tumor tissue, allowing enhanced uptake by cancer cells. These properties translate into clinical utility in recurrent ovarian cancer as demonstrated by phase II and III trials, this proven clinical efficacy leading to FDA approval in second-line therapy for ovarian cancer. New combinations with cytotoxics, in particular with carboplatin, have demonstrated an acceptable toxicity profile and clinical utility in platinum-sensitive ovarian cancer. A favorable toxicity profile renders liposomal doxorubicin an ideal partner for combination regimens with other cytotoxics, and more recently with biological agents. Such combinations are the subject of ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)639-650
Number of pages12
JournalTherapeutics and Clinical Risk Management
Volume5
Issue number1
StatePublished - Dec 1 2009

Keywords

  • Doxorubicin
  • Liposomes
  • Ovarian cancer
  • Pegylated liposomal doxorubicin

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Pegylated liposomal doxorubicin in ovarian cancer'. Together they form a unique fingerprint.

Cite this